How does disitamab vedotin-based therapy work for metastatic urothelial carcinoma patients?
Disitamab vedotin (DV) is an antibody-drug conjugate (ADC) that works like a guided missile. It targets a protein called HER2 on the surface of urothelial cancer cells. Once attached, it releases a powerful chemotherapy drug directly inside the cancer cell, killing it. For metastatic urothelial carcinoma (UC), DV is often combined with a PD-1 inhibitor (a type of immunotherapy) to enhance the immune system's ability to fight the cancer. This combination approach has shown promising results in clinical studies.
What the research says
A 2025 systematic review and meta-analysis of 16 studies found that DV-based therapy in HER2-negative and HER2-low metastatic UC achieved an objective response rate (ORR) of 51% and a disease control rate (DCR) of 75%, with a median progression-free survival (mPFS) of 5.48 months 37. The response was better in HER2-low patients (ORR 55%) compared to HER2-negative patients (ORR 34%) 37.
A real-world study across six centers in China evaluated DV combined with a PD-1 inhibitor in 132 patients with locally advanced or metastatic UC. The combination showed high response rates and manageable safety 4. This suggests that adding immunotherapy may boost the effectiveness of DV.
The phase 3 trial SGNDV-001 is currently testing DV plus pembrolizumab (a PD-1 inhibitor) versus chemotherapy as a first-line treatment for HER2-expressing metastatic UC. The trial aims to see if this combination improves progression-free survival and overall survival 6.
A network meta-analysis of 30 studies confirmed that ADC-based therapies, including DV, are effective in UC, though they have a higher rate of serious side effects compared to standard therapy 8.
What to ask your doctor
- Is my tumor tested for HER2 expression, and what does that mean for treatment options?
- Would I be a candidate for disitamab vedotin, either alone or combined with a PD-1 inhibitor?
- What are the possible side effects of disitamab vedotin and how are they managed?
- Are there any ongoing clinical trials for disitamab vedotin that I might be eligible for?
- How does disitamab vedotin compare to other treatments like enfortumab vedotin for my situation?
This question is drawn from common patient questions about this topic and answered using cited medical research. We do not provide individualized advice.